
Opinion|Videos|September 25, 2024
Redefining Vitiligo Management: FDA-Approved Topical Ruxolitinib and the Evolving Treatment Paradigm
Author(s)Pearl Grimes, MD, FAAD
Pearl E. Grimes, MD, discusses the evolving treatment paradigm for vitiligo, highlighting the role of FDA-approved topical ruxolitinib and its impact on management strategies.
Advertisement
Episodes in this series

Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Delgocitinib Advances to Phase 3 Evaluation for Lichen Sclerosus
2
The “6-7” Advances for Dermatologists to Look Forward to in 2026
3
Obagi Launches ALOHA Program to Capture Real-World Insights in Aesthetic Injectables
4
Quoin Targets World’s First Approval for Netherton Syndrome Therapy in Saudi Arabia
5















